Cargando…
Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
The prognostic and predictive value of sequencing analysis in myelodysplastic syndromes (MDS) has not been fully integrated into clinical practice. We performed whole exome sequencing (WES) of bone marrow samples from 83 patients with MDS and 31 with MDS/MPN identifying 218 driver mutations in 31 ge...
Autores principales: | Montalban-Bravo, Guillermo, Takahashi, Koichi, Patel, Keyur, Wang, Feng, Xingzhi, Song, Nogueras, Graciela M., Huang, Xuelin, Pierola, Ana Alfonso, Jabbour, Elias, Colla, Simona, Gañan-Gomez, Irene, Borthakur, Gautham, Daver, Naval, Estrov, Zeev, Kadia, Tapan, Pemmaraju, Naveen, Ravandi, Farhad, Bueso-Ramos, Carlos, Chamseddine, Ali, Konopleva, Marina, Zhang, Jianhua, Kantarjian, Hagop, Futreal, Andrew, Garcia-Manero, Guillermo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839396/ https://www.ncbi.nlm.nih.gov/pubmed/29515765 http://dx.doi.org/10.18632/oncotarget.23882 |
Ejemplares similares
-
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
por: Takahashi, Koichi, et al.
Publicado: (2016) -
Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
por: Daver, Naval, et al.
Publicado: (2017) -
P736: ANALYSIS OF RESPONSE RATES AND OUTCOMES IN ERYTHROID-PREDOMINANT MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH VENETOCLAX-BASED REGIMENS
por: Bazinet, Alexandre, et al.
Publicado: (2023) -
IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
por: DiNardo, Courtney D, et al.
Publicado: (2015) -
Acute myeloid leukemia: current progress and future directions
por: Kantarjian, Hagop, et al.
Publicado: (2021)